The Management

Mark S. Duxon PhD

mark_duxon_400Mark joined Transpharmation in late 2011 as CEO following several years working as a CEO of preclinical/translational Contract Research Organisations (e.g. Porsolt (France), Maccine (Singapore)).

Mark joined Transpharmation in late 2011 as CEO following several years working as a CEO of preclinical/translational Contract Research Organisations (e.g. Porsolt (France), Maccine (Singapore)). Mark is an experienced international commercial leader with a track record of growing drug discovery and pharma service businesses via organic growth and through raising capital. He has several Non-Executive Director positions and recently founded Varsity Biologisitcs to provide sample shipment support to the global pharma industry. Mark is a Molecular Biologist and Neuropharmacologist by training, obtaining his PhD at the University of Nottingham before embarking on a career in several major Pharma companies including GSK. He has lead several Drug Discovery programmes into preclinical development across Psychiatric and Neurological therapeutic areas and has worked extensively in the product support of the antidepressant Paxil/Seroxat (paroxetine). Mark, set up and established GSK’s Center for Cognitive and Neurodegenerative Disease in Singapore in 2003.

Neil Upton PhD

Prior to setting up Transpharmation in 2010, Neil gained extensive drug discovery know-how working for over 25 years in major Pharma companies (SmithKline Beecham, GlaxoSmithKline)

Prior to setting up Transpharmation in 2010, Neil gained extensive drug discovery know-how working for over 25 years in major Pharma companies (SmithKline Beecham, GlaxoSmithKline). This involved leading multidisciplinary teams of up to 40 preclinical and clinical translational scientists specializing in diverse CNS and GI indications. He has been the strategic leader on several portfolios including Alzheimer’s disease, schizophrenia, pain, epilepsy and sleep disorders. Neil has taken molecules directed to numerous targets through Discovery and into clinical trials. These include 5-HT6, H3 and OX1/2 receptors and GAP junction modulators. Neil is the author of several patents, continues to publish and support the educational efforts of the British Pharmacological Society of which he is a Fellow.